Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

Biofrontera (BFRIW) Gains from Sales and Divestitures (2022 - 2025)

Biofrontera has reported Gains from Sales and Divestitures over the past 4 years, most recently at $225000.0 for Q4 2025.

  • Quarterly results put Gains from Sales and Divestitures at $225000.0 for Q4 2025, up 4615.99% from a year ago — trailing twelve months through Dec 2025 was $225000.0 (up 4615.99% YoY), and the annual figure for FY2025 was $225000.0, up 4615.99%.
  • Gains from Sales and Divestitures for Q4 2025 was $225000.0 at Biofrontera, roughly flat from $225000.0 in the prior quarter.
  • Over the last five years, Gains from Sales and Divestitures for BFRIW hit a ceiling of $170.1 million in Q2 2022 and a floor of $4771.0 in Q2 2024.
  • Median Gains from Sales and Divestitures over the past 4 years was $8588.0 (2023), compared with a mean of $17.1 million.
  • Biggest five-year swings in Gains from Sales and Divestitures: crashed 94.95% in 2023 and later soared 4615.99% in 2025.
  • Biofrontera's Gains from Sales and Divestitures stood at $8504.0 in 2022, then rose by 0.99% to $8588.0 in 2023, then plummeted by 44.45% to $4771.0 in 2024, then soared by 4615.99% to $225000.0 in 2025.
  • The last three reported values for Gains from Sales and Divestitures were $225000.0 (Q4 2025), $225000.0 (Q3 2025), and $4771.0 (Q4 2024) per Business Quant data.